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Nanomedicine, an emerging new field created by the fusion of nanotechnology and
medicine, is one of the most promising pathways for the development of effective
targeted therapies with oncology being the earlier and the most notable beneficiary
to date. Indeed, drug-loaded nanosystems provide an ideal solution to overcome the
low selectivity of the anticancer drugs towards the cancer cells in regards to normal
cells and the induced severe side effects, thanks to their passive and/or active
targeting to cancer tissues. Nanoparticle and liposome-based systems encapsulating
drugs are already used in some cancer therapies. They can be classified according to
their stability in the blood stream. For stable systems, the first generation of
nanocarriers targets the reticulo-endothelial system (RES) due to opsonization that
occurs on the nanocarrier surface. Even though this way of targeting is simple, a
number of nanomedicines are on the market (Myocet®/breast cancer,
Daunoxome®/Kaposi’s sarcoma, Vyxeos®/acute myeloid leukemia,…). From this
point, RES-avoiding nanocarriers have been developed and allow a passive targeting
of the tumors based on the enhanced permeability and retention effect (EPR): they
constitute the second generation with specialities on the market such as Caelyx®
(ovarian cancer), Onivyde® (pancreas cancer)… in therapeutics or Sinerem® in
diagnostics. A third generation of nanocarriers is under development where a ligand
is attached to the nanosystem surface to recognize a specific biomarker
overexpressed by the cancer cells. However, the mechanism of action of the two
latter generations of nanocarriers relies on the EPR effect. Unfortunately, many
aggressive tumors are poorly vascularized what represents a severe limitation for
these nanomedicines. Some advances have been made with unstable nanoparticles in
the blood stream such as albumin-based nanocarriers (Abraxane®). An original
mechanism of action makes them useful as an adjuvant therapy for tumors such as
the pancreatic adenocarcinoma for instance. Another strategy that allows to bypass
the EPR effect in poorly vascularized cancers is the local administration of
nanocarriers, directly in the tumor. In such cases, this is a physical change that is
sought after (hyperthermia, ionizing radiations,…). Nevertheless improvements are
needed in drug targeting using nanoparticle-based strategies, such as more stable
formulations that do not leak, more versatile systems able to encapsulate any type of
drugs, control of active and sub-cellular targeting,… In a near future, nanosystems
capable to diagnose and to treat at the same time a tumor will appear on the market,
opening an era of theranostics
URL de la
notice http://okina.univ-angers.fr/publications/ua17218 [2]
Lien vers le
document en
ligne
https://www.bibalex.org/bva2018/home/home.aspx [3]
Liens
[1] http://okina.univ-angers.fr/j.benoit/publications
[2] http://okina.univ-angers.fr/publications/ua17218
[3] https://www.bibalex.org/bva2018/home/home.aspx
Publié sur Okina (http://okina.univ-angers.fr)
